STOCK TITAN

[SCHEDULE 13G/A] Skye Bioscience, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Schonfeld Strategic Advisors LLC filed an amendment to a Schedule 13G reporting ownership of 1,115,939 shares of Skye Bioscience, Inc. common stock, representing 3.60% of the class. The filing states those shares are held for the ordinary course of business and not for the purpose of influencing control. Schonfeld reports sole voting and dispositive power over the reported shares and notes that some shares are held in separately managed accounts for clients who retain the right to dividends or sale proceeds.

Schonfeld Strategic Advisors LLC ha presentato un emendamento al Schedule 13G dichiarando la proprietà di 1,115,939 azioni ordinarie di Skye Bioscience, Inc., pari al 3,60% della classe. La documentazione precisa che tali azioni sono detenute nell'ordinario svolgimento dell'attività e non con l'intento di influenzare il controllo. Schonfeld dichiara di avere il pieno diritto di voto e di disposizione sulle azioni segnalate e osserva che alcune azioni sono detenute in conti gestiti separatamente per clienti che mantengono il diritto ai dividendi o al ricavato della vendita.

Schonfeld Strategic Advisors LLC presentó una enmienda al Schedule 13G informando la propiedad de 1,115,939 acciones ordinarias de Skye Bioscience, Inc., que representan el 3,60% de la clase. La presentación indica que esas acciones se mantienen en el curso ordinario del negocio y no con el propósito de influir en el control. Schonfeld informa tener el poder exclusivo de voto y de disposición sobre las acciones reportadas y señala que algunas acciones se mantienen en cuentas gestionadas por separado para clientes que conservan el derecho a los dividendos o al producto de la venta.

Schonfeld Strategic Advisors LLC는 Schedule 13G 수정서를 제출하여 Skye Bioscience, Inc.의 보통주 1,115,939주를 보유하고 있으며 이는 해당 등급의 3.60%에 해당한다고 보고했습니다. 제출서에는 해당 주식들이 영업의 통상적인 범위에서 보유되고 있으며 지배권 행사 목적이 아님을 명시하고 있습니다. Schonfeld는 보고된 주식에 대해 단독 의결권 및 처분권을 보유하고 있음을 보고하며, 일부 주식은 배당금 또는 매각대금에 대한 권리를 보유한 고객을 위해 별도 관리 계좌에 보관되어 있음을 언급하고 있습니다.

Schonfeld Strategic Advisors LLC a déposé un amendement au Schedule 13G déclarant la détention de 1,115,939 actions ordinaires de Skye Bioscience, Inc., représentant 3,60% de la catégorie. le dépôt précise que ces actions sont détenues dans le cours normal des affaires et non dans le but d'influencer le contrôle. Schonfeld indique détenir le pouvoir de vote et le pouvoir de disposition exclusifs sur les actions déclarées et signale que certaines actions sont détenues dans des comptes gérés séparément pour des clients qui conservent le droit aux dividendes ou au produit de la vente.

Schonfeld Strategic Advisors LLC hat eine Änderung zu einem Schedule 13G eingereicht und meldet den Besitz von 1,115,939 Aktien von Skye Bioscience, Inc. Stammaktien, was 3,60% der Klasse entspricht. Die Einreichung besagt, dass diese Aktien im normalen Geschäftsverlauf gehalten werden und nicht mit dem Zweck, die Kontrolle zu beeinflussen. Schonfeld berichtet, über die gemeldeten Aktien alleinige Stimm- und Verfügungsgewalt zu haben und weist darauf hin, dass einige Aktien in separat verwalteten Konten für Kunden gehalten werden, die das Recht auf Dividenden oder Verkaufserlöse behalten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine Schedule 13G/A disclosing a sub-5% passive stake, indicating monitoring rather than activist intent.

The filing reports a 3.60% stake (1,115,939 shares) held with sole voting and dispositive power by Schonfeld Strategic Advisors LLC. Under applicable rules, this level of ownership is below the 5% threshold that typically triggers more intensive disclosure and potential activist signaling. The certification language expressly states the position is held in the ordinary course of business and not to influence control, which supports a non-activist posture. For investors, this is a transparency disclosure rather than a material governance event.

TL;DR: Disclosure aligns with standard governance practice for institutional holders below 5%.

The amendment clarifies beneficial ownership and confirms sole voting and dispositive authority for the reported shares. Schonfeld also notes ownership may include securities held in Schonfeld-managed SMAs where clients are record owners and retain economic rights. No group affiliation or control assertions are made. This filing does not indicate a change in control intent and is consistent with routine reporting obligations under the Exchange Act.

Schonfeld Strategic Advisors LLC ha presentato un emendamento al Schedule 13G dichiarando la proprietà di 1,115,939 azioni ordinarie di Skye Bioscience, Inc., pari al 3,60% della classe. La documentazione precisa che tali azioni sono detenute nell'ordinario svolgimento dell'attività e non con l'intento di influenzare il controllo. Schonfeld dichiara di avere il pieno diritto di voto e di disposizione sulle azioni segnalate e osserva che alcune azioni sono detenute in conti gestiti separatamente per clienti che mantengono il diritto ai dividendi o al ricavato della vendita.

Schonfeld Strategic Advisors LLC presentó una enmienda al Schedule 13G informando la propiedad de 1,115,939 acciones ordinarias de Skye Bioscience, Inc., que representan el 3,60% de la clase. La presentación indica que esas acciones se mantienen en el curso ordinario del negocio y no con el propósito de influir en el control. Schonfeld informa tener el poder exclusivo de voto y de disposición sobre las acciones reportadas y señala que algunas acciones se mantienen en cuentas gestionadas por separado para clientes que conservan el derecho a los dividendos o al producto de la venta.

Schonfeld Strategic Advisors LLC는 Schedule 13G 수정서를 제출하여 Skye Bioscience, Inc.의 보통주 1,115,939주를 보유하고 있으며 이는 해당 등급의 3.60%에 해당한다고 보고했습니다. 제출서에는 해당 주식들이 영업의 통상적인 범위에서 보유되고 있으며 지배권 행사 목적이 아님을 명시하고 있습니다. Schonfeld는 보고된 주식에 대해 단독 의결권 및 처분권을 보유하고 있음을 보고하며, 일부 주식은 배당금 또는 매각대금에 대한 권리를 보유한 고객을 위해 별도 관리 계좌에 보관되어 있음을 언급하고 있습니다.

Schonfeld Strategic Advisors LLC a déposé un amendement au Schedule 13G déclarant la détention de 1,115,939 actions ordinaires de Skye Bioscience, Inc., représentant 3,60% de la catégorie. le dépôt précise que ces actions sont détenues dans le cours normal des affaires et non dans le but d'influencer le contrôle. Schonfeld indique détenir le pouvoir de vote et le pouvoir de disposition exclusifs sur les actions déclarées et signale que certaines actions sont détenues dans des comptes gérés séparément pour des clients qui conservent le droit aux dividendes ou au produit de la vente.

Schonfeld Strategic Advisors LLC hat eine Änderung zu einem Schedule 13G eingereicht und meldet den Besitz von 1,115,939 Aktien von Skye Bioscience, Inc. Stammaktien, was 3,60% der Klasse entspricht. Die Einreichung besagt, dass diese Aktien im normalen Geschäftsverlauf gehalten werden und nicht mit dem Zweck, die Kontrolle zu beeinflussen. Schonfeld berichtet, über die gemeldeten Aktien alleinige Stimm- und Verfügungsgewalt zu haben und weist darauf hin, dass einige Aktien in separat verwalteten Konten für Kunden gehalten werden, die das Recht auf Dividenden oder Verkaufserlöse behalten.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage of the issuer's common stock beneficially owned by the reporting person reflects 30,988,420 shares of common stock outstanding as of August 5, 2025, as set forth in the issuer's Quarterly Report on Form 10-Q filed by the issuer with the Securities and Exchange Commission on August 7, 2025.


SCHEDULE 13G



Schonfeld Strategic Advisors LLC
Signature:/s/ Hung Luc
Name/Title:Hung Luc, Chief Compliance Officer
Date:08/14/2025
Skye Bioscience

NASDAQ:SKYE

SKYE Rankings

SKYE Latest News

SKYE Latest SEC Filings

SKYE Stock Data

100.71M
30.50M
1.44%
80.76%
8.65%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO